Biomolecules & Therapeutics : eISSN 2005-4483 / pISSN 1976-9148

Download original image
Fig. 3. VPA enhances CaV3.1 expression by inhibiting histone deacetylase. (A) Cacna1g mRNA levels analyzed through real-time PCR 24 h after treatment with vehicle, VPA or valpromide in NPCs. Treatment with VPA, but not VPM, increased the levels of Cacna1g mRNA, compared to vehicle treatment (N=11 per group, Kruskal-Wallis test followed by Dunn’s multiple comparison test, H=7.928, p=0.0190). (B) Protein levels of CaV3.1 and acetylated histone H3 in NPCs and quantitative analysis of CaV3.1 protein levels. β-actin was used as a loading control for quantification of the proteins on blots. CaV3.1 protein levels were increased by VPA, TSA, and SB, compared to vehicle treatment (N=4-5, one-way ANOVA followed by t-test, F(4, 19)=3.374, p=0.0302). Data are presented as mean ± SEM. *p<0.05 and **p<0.01.
Biomolecules & Therapeutics 2020;28:389~396 https://doi.org/10.4062/biomolther.2020.027
© Biomolecules & Therapeutics